{"id":"camrelizumab-plus-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Decreased appetite"},{"rate":"5-10","effect":"Immune-related pneumonitis"},{"rate":"3-8","effect":"Immune-related hepatitis"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"15-25","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL4297715","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Camrelizumab binds to programmed death receptor-1 (PD-1) on T lymphocytes, preventing engagement with its ligands (PD-L1 and PD-L2) expressed on tumor and immune cells. This blockade reverses T cell exhaustion and restores cytotoxic T cell function against cancer cells. When combined with chemotherapy, the immunological priming from chemotherapy is enhanced by the checkpoint inhibition, improving overall anti-tumor efficacy.","oneSentence":"Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:44.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC) in combination with chemotherapy"},{"name":"Nasopharyngeal carcinoma in combination with chemotherapy"},{"name":"Esophageal squamous cell carcinoma in combination with chemotherapy"}]},"trialDetails":[{"nctId":"NCT07320586","phase":"PHASE2","title":"Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Shandong Tumor Hospital","startDate":"2021-03-01","conditions":"Gastric Cancer, Second-line Therapy","enrollment":40},{"nctId":"NCT07471815","phase":"PHASE2","title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harbin Medical University","startDate":"2026-03-04","conditions":"Breast Cancer Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT04928807","phase":"PHASE3","title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-07-20","conditions":"Rectal Cancer","enrollment":231},{"nctId":"NCT07432087","phase":"PHASE3","title":"Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Yue He, MD","startDate":"2026-02-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":246},{"nctId":"NCT06802757","phase":"PHASE2","title":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-01","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT07397442","phase":"PHASE2","title":"Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2026-03-01","conditions":"Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":19},{"nctId":"NCT07401199","phase":"","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","status":"NOT_YET_RECRUITING","sponsor":"Qun Zhao","startDate":"2026-02-05","conditions":"Gastric Cancer (GC), Locally Advanced Gastric Cancer","enrollment":2000},{"nctId":"NCT05139095","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-01-27","conditions":"Gestational Trophoblastic Neoplasia","enrollment":70},{"nctId":"NCT07332247","phase":"PHASE2","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-03","conditions":"Nasopharangeal Cancer, Recurrent Nasopharynx Carcinoma","enrollment":94},{"nctId":"NCT07162506","phase":"PHASE2","title":"DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-08-01","conditions":"Esophageal Cancer","enrollment":120},{"nctId":"NCT03092895","phase":"PHASE2","title":"A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-04-24","conditions":"Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma","enrollment":157},{"nctId":"NCT06631326","phase":"","title":"HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)","status":"COMPLETED","sponsor":"First Hospital of China Medical University","startDate":"2021-01-01","conditions":"HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, BCLC Stage C Hepatocellular Carcinoma","enrollment":244},{"nctId":"NCT05198609","phase":"PHASE3","title":"Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-17","conditions":"Hepatocellular Carcinoma","enrollment":214},{"nctId":"NCT04342910","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-21","conditions":"Gastric Cancer","enrollment":550},{"nctId":"NCT05524168","phase":"PHASE2","title":"SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-11-25","conditions":"Nasopharyngeal Carcinoma","enrollment":41},{"nctId":"NCT07167160","phase":"PHASE2","title":"Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03-10","conditions":"Cervical Cancer, Immunochemotherapy","enrollment":59},{"nctId":"NCT07267806","phase":"PHASE3","title":"Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC","status":"RECRUITING","sponsor":"Linhui Peng","startDate":"2025-10-31","conditions":"Hepato Cellular Carcinoma (HCC), Chemotherapy Effect","enrollment":326},{"nctId":"NCT06866951","phase":"PHASE2, PHASE3","title":"A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial","status":"WITHDRAWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03-01","conditions":"Cervical Cancers","enrollment":""},{"nctId":"NCT06561308","phase":"PHASE2","title":"Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-09-01","conditions":"Endometrioid Endometrial Cancer","enrollment":39},{"nctId":"NCT07251062","phase":"PHASE2, PHASE3","title":"A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-12-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":737},{"nctId":"NCT07235319","phase":"PHASE3","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-20","conditions":"Nasopharangeal Cancer, Distant Metastasis","enrollment":260},{"nctId":"NCT07236320","phase":"NA","title":"Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC","status":"COMPLETED","sponsor":"Yongtao Han","startDate":"2018-03-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":200},{"nctId":"NCT06869226","phase":"PHASE2","title":"A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-04-30","conditions":"Esophageal Cancer","enrollment":283},{"nctId":"NCT07190027","phase":"PHASE1, PHASE2","title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-11","conditions":"Advanced Non-Small Cell Lung Cancer (NSCLC)","enrollment":246},{"nctId":"NCT04619433","phase":"PHASE3","title":"A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-02-01","conditions":"Non-squamous Non-small-cell Lung Cancer","enrollment":48},{"nctId":"NCT07181850","phase":"","title":"Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features","status":"COMPLETED","sponsor":"Nanjing Medical University","startDate":"2019-01-01","conditions":"Esophageal Squamous Cell Carcinoma, Pathological Complete Response","enrollment":363},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT04906993","phase":"PHASE3","title":"Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-07-23","conditions":"Cervical Cancer","enrollment":443},{"nctId":"NCT07161791","phase":"PHASE1, PHASE2","title":"Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2025-09-15","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":12},{"nctId":"NCT07107217","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-08","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT07057089","phase":"PHASE2","title":"Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-07-01","conditions":"Locally Advanced Rectal Cancer","enrollment":90},{"nctId":"NCT06323382","phase":"","title":"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab","enrollment":240},{"nctId":"NCT05673577","phase":"PHASE2","title":"Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-03-22","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":40},{"nctId":"NCT06896422","phase":"PHASE1","title":"Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-06-01","conditions":"Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody","enrollment":80},{"nctId":"NCT04680988","phase":"PHASE2","title":"A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-05","conditions":"Recurrent or Metastatic Cervical Cancer","enrollment":194},{"nctId":"NCT05156970","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2021-06-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":81},{"nctId":"NCT07053215","phase":"NA","title":"Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC","status":"COMPLETED","sponsor":"The First Hospital of Hebei Medical University","startDate":"2020-12-01","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":60},{"nctId":"NCT03777124","phase":"PHASE2","title":"Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-11","conditions":"NSCLC Stage IV, KRAS Gene Mutation, PD-1 Antibody","enrollment":25},{"nctId":"NCT06811844","phase":"PHASE2","title":"Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-02-25","conditions":"Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy","enrollment":208},{"nctId":"NCT06435260","phase":"PHASE2","title":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-08-01","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT04625803","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Colon Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2021-01-04","conditions":"Colon Cancer, Neoadjuvant Therapy","enrollment":64},{"nctId":"NCT07016737","phase":"PHASE3","title":"Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy","status":"ENROLLING_BY_INVITATION","sponsor":"Ye jinjun","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":79},{"nctId":"NCT06889688","phase":"PHASE3","title":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-04-01","conditions":"Breast Cancer Stage IV","enrollment":246},{"nctId":"NCT06926179","phase":"","title":"Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-12-01","conditions":"Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy","enrollment":500},{"nctId":"NCT06901622","phase":"PHASE2","title":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-11-08","conditions":"Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","enrollment":50},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT06288360","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy in PD-L1-negative LACC","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-09-12","conditions":"Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative","enrollment":40},{"nctId":"NCT04510064","phase":"PHASE2","title":"Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial","status":"COMPLETED","sponsor":"Fudan University","startDate":"2021-01-06","conditions":"Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma, Gastric Cancer Adenocarcinoma Metastatic","enrollment":40},{"nctId":"NCT06796803","phase":"PHASE2, PHASE3","title":"Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-02-20","conditions":"Potentially Resectable Hepatocellular Carcinoma","enrollment":398},{"nctId":"NCT06333561","phase":"","title":"HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor","enrollment":300},{"nctId":"NCT05475678","phase":"PHASE2","title":"Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Zhenzhen Liu","startDate":"2022-12-20","conditions":"Breast Cancer, Triple Negative Breast Cancer, Camrelizumab","enrollment":369},{"nctId":"NCT04649476","phase":"PHASE2","title":"Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2021-03-22","conditions":"Oral Squamous Cell Carcinoma","enrollment":68},{"nctId":"NCT06759090","phase":"PHASE2","title":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-01-15","conditions":"Metastatic Pancreatic Carcinoma","enrollment":43},{"nctId":"NCT06669611","phase":"PHASE3","title":"Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-27","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":242},{"nctId":"NCT06702566","phase":"NA","title":"The Effect of Serum Ferritin in irAE","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-04","conditions":"Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia","enrollment":1500},{"nctId":"NCT05738434","phase":"PHASE2","title":"Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2023-03-02","conditions":"Esophageal Cancer by AJCC V8 Stage","enrollment":188},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06636591","phase":"NA","title":"Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-11-18","conditions":"Breast Cancer Female, HER2-negative Breast Cancer","enrollment":14},{"nctId":"NCT06289062","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-05-08","conditions":"Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation","enrollment":40},{"nctId":"NCT05003700","phase":"PHASE2","title":"Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-08-12","conditions":"Hepatocellular Carcinoma","enrollment":39},{"nctId":"NCT06675214","phase":"PHASE3","title":"Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-30","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":586},{"nctId":"NCT04294784","phase":"PHASE2","title":"Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer","status":"TERMINATED","sponsor":"Huazhong University of Science and Technology","startDate":"2020-04-03","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":58},{"nctId":"NCT06288373","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-04-22","conditions":"Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy","enrollment":440},{"nctId":"NCT05043688","phase":"PHASE3","title":"Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.","status":"RECRUITING","sponsor":"Zhigang Li","startDate":"2021-09-01","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":426},{"nctId":"NCT06632106","phase":"","title":"HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2024-08-16","conditions":"Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors","enrollment":97},{"nctId":"NCT06632093","phase":"","title":"HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC","status":"RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2024-09-16","conditions":"BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy","enrollment":84},{"nctId":"NCT06607107","phase":"PHASE2","title":"mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-02-17","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":29},{"nctId":"NCT04515615","phase":"PHASE2","title":"Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yu jiren","startDate":"2020-09-09","conditions":"Gastric Cancer Stage III","enrollment":52},{"nctId":"NCT05412589","phase":"PHASE2","title":"mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-06-10","conditions":"Stage III Hepatocellular Cancer (CNLC Staging)","enrollment":35},{"nctId":"NCT05554276","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","startDate":"2023-08-01","conditions":"Neoadjuvant Chemotherapy, PD-1 Antibody, Radiotherapy","enrollment":36},{"nctId":"NCT06516445","phase":"PHASE2","title":"SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2023-06-28","conditions":"Colorectal Cancer","enrollment":33},{"nctId":"NCT06086457","phase":"PHASE3","title":"PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-02-04","conditions":"Esophageal Neoplasms","enrollment":436},{"nctId":"NCT06438627","phase":"PHASE3","title":"Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-30","conditions":"Nasopharyngeal Carcinoma","enrollment":164},{"nctId":"NCT04715633","phase":"PHASE2","title":"PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-12-01","conditions":"Colorectal Cancer, Microsatellite Instability High","enrollment":53},{"nctId":"NCT06485466","phase":"PHASE3","title":"TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Guohui Xu","startDate":"2024-07-01","conditions":"Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab","enrollment":101},{"nctId":"NCT06485271","phase":"","title":"A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Changzhi People's Hospital Affiliated to Changzhi Medical College","startDate":"2023-11-01","conditions":"Gastric Cancer, RWS, PD-1 Immunotherapy","enrollment":504},{"nctId":"NCT06339060","phase":"PHASE3","title":"An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-05-01","conditions":"Esophageal Cancer","enrollment":356},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT06423170","phase":"PHASE2","title":"A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":"Unresectable Gallbladder Cancer","enrollment":37},{"nctId":"NCT05128201","phase":"PHASE2","title":"Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2021-12-01","conditions":"Oligometastatic Disease","enrollment":63},{"nctId":"NCT06376721","phase":"PHASE1, PHASE2","title":"Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2024-04-14","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma","enrollment":43},{"nctId":"NCT06376773","phase":"","title":"Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.","status":"COMPLETED","sponsor":"Fujian Medical University","startDate":"2022-06-01","conditions":"Advanced Gastric Cancer, Neoadjuvant Therapy, Multi-omics Analysis","enrollment":234},{"nctId":"NCT05134194","phase":"PHASE3","title":"A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-01-17","conditions":"Triple Negative Breast Cancer","enrollment":1},{"nctId":"NCT06356701","phase":"PHASE1","title":"Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2024-04-15","conditions":"Long-Term Effects Secondary to Cancer Therapy","enrollment":120},{"nctId":"NCT06354530","phase":"PHASE2, PHASE3","title":"A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Army Medical Center of PLA","startDate":"2024-03-08","conditions":"Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma","enrollment":266},{"nctId":"NCT06346808","phase":"PHASE1","title":"Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2024-05-01","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT05798793","phase":"PHASE3","title":"Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2023-11-21","conditions":"Oral Squamous Cell Carcinoma","enrollment":309},{"nctId":"NCT06231680","phase":"PHASE2","title":"Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2024-01-19","conditions":"Lung Cancer, Nonsmall Cell, Esophageal Carcinoma","enrollment":132},{"nctId":"NCT06335355","phase":"PHASE2, PHASE3","title":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2024-03","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":401},{"nctId":"NCT04613674","phase":"PHASE3","title":"A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-12-09","conditions":"Triple Negative Breast Cancer","enrollment":441},{"nctId":"NCT06326736","phase":"EARLY_PHASE1","title":"Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Jinling Hospital, China","startDate":"2024-04","conditions":"Pancreatic Cancer","enrollment":12},{"nctId":"NCT06032052","phase":"PHASE2","title":"Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients","status":"RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2024-02-01","conditions":"Elderly Patients, Metastatic Lung Cancer","enrollment":49},{"nctId":"NCT06313463","phase":"PHASE3","title":"Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-03","conditions":"Breast Neoplasms","enrollment":375},{"nctId":"NCT06304545","phase":"PHASE2","title":"Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-03-15","conditions":"Rectal Cancer","enrollment":48},{"nctId":"NCT05101616","phase":"PHASE1, PHASE2","title":"A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer","status":"SUSPENDED","sponsor":"Shanghai Minimally Invasive Surgery Center","startDate":"2022-07-01","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT05011227","phase":"PHASE2","title":"Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2021-08-10","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":100},{"nctId":"NCT03711279","phase":"PHASE2","title":"A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-11-22","conditions":"Sarcoma","enrollment":99},{"nctId":"NCT06276933","phase":"PHASE4","title":"A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Tongji University","startDate":"2024-02-22","conditions":"Lung Cancer, Camrelizumab","enrollment":104},{"nctId":"NCT05999149","phase":"PHASE3","title":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-08-20","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":424},{"nctId":"NCT06241807","phase":"PHASE2","title":"Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2022-12-02","conditions":"IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":117,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Camrelizumab Plus Chemotherapy","genericName":"Camrelizumab Plus Chemotherapy","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camrelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, restoring anti-tumor immune responses. Used for Non-small cell lung cancer (NSCLC) in combination with chemotherapy, Nasopharyngeal carcinoma in combination with chemotherapy, Esophageal squamous cell carcinoma in combination with chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}